Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026

A securities class action has been filed against Capricor Therapeutics on behalf of investors who held shares from December 17, 2025 through July 26, 2026, with a lead-plaintiff deadline of September 28, 2026. The complaint alleges Capricor changed the pre-specified statistical analysis plan for its resubmitted Dermamiocel BLA without obtaining FDA review or agreement before submission. Following FDA briefing documents released July 27, 2026, Capricor shares fell $12.70, or 64%, to $7.00.

Analysis

The litigation notice is not an incremental fundamental catalyst; it monetizes information already reflected in CAPR's prior repricing. The relevant valuation issue remains whether FDA’s process and data-integrity concerns impair approvability, not the likely settlement cost, which is generally immaterial relative to a pre-commercial biotech’s regulatory binary. A prolonged review or a request for additional controlled evidence would shift the equity from an approval-probability valuation toward a cash-runway/dilution valuation, with the financing overhang likely becoming more important than the lawsuit over the next 3-12 months.

CAPR's post-gap volatility makes an outright short unattractive without confirmed borrow and a defined regulatory calendar: a favorable advisory-committee or FDA signal could generate a sharp squeeze from depressed levels. Conversely, any indication that the analysis-plan issue cannot be cured through labeling, post-marketing commitments, or an amended submission would likely reset expected launch timing by years rather than quarters. The second-order beneficiary is SRPT, whose Duchenne franchise retains greater strategic value if a potential cardiomyopathy-focused competitor is delayed, although SRPT's own regulatory and safety risks make this only a relative, not absolute, read-through.

Consensus may over-weight the plaintiff-law-firm headline and under-weight the financing pathway. Securities suits commonly follow large single-day declines and do not independently establish misconduct; the actionable signal is whether management updates cash runway, defends the original analysis methodology, or changes development spending. Until those disclosures are available, this is a regulatory-surveillance situation rather than a high-conviction litigation trade.

Key Decisions for Investors

• Do not initiate a CAPR position solely on the litigation notice; maintain no/underweight exposure until the next FDA-facing event, cash balance, quarterly burn, and any revised regulatory timeline are verified.
• Set a CAPR downside alert for a disclosed need for a new pivotal study or BLA withdrawal/refusal-to-file outcome; that would materially raise dilution risk and could support a short only if borrow is available and position size is capped for binary-event gap risk.
• For a 1-3 month relative-value watch, monitor long SRPT versus short CAPR only after confirmation that CAPR faces a material review delay. Exit the pair if FDA accepts a remediation path without new efficacy work, since CAPR could rebound disproportionately.
• Treat a management reaffirmation of cash runway through the next definitive FDA decision, plus evidence that the statistical-plan issue is remediable, as falsification of the bearish dilution thesis; avoid maintaining any CAPR short through that disclosure or an advisory-committee event.